News | July 17, 2024
Lupin divests US commercial women's health specialty business to Evofem
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
The approved ANDA is therapeutically equivalent to the reference listed drug product
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
The academy has secured partnerships with 15 esteemed hospitals
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Subscribe To Our Newsletter & Stay Updated
